Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusiness
Last Updated : Jun 14, 2019 07:03 PM IST | Source: PTI

Laurus Labs gets 2 observations from USFDA for Unit 1 & 3 at Visakhapatnam

The company, however, did not share any details about the observations made by the regulator.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Laurus Labs June 14 said the US health regulator has made two observations after the inspection of its Visakhapatnam facility in Andhra Pradesh.

The company has completed the United States Food and Drug Administration (USFDA) inspection of its active pharmaceutical ingredient (API) facilities in Units 1 and 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations, Laurus Labs said in a filing to the BSE.

The observations are procedural in nature, it added.

Close

"This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection," Laurus Labs said.

The company, however, did not share any details about the observations made by the regulator.

Shares of Laurus Labs Friday closed at Rs 338.70 per scrip on the BSE, up 0.82 per cent from its previous close.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Jun 14, 2019 07:03 pm
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant